MoonLake Immunotherapeutics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, MoonLake Immunotherapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 2 completed later-stage tilt upper quartile by trial count

MoonLake Immunotherapeutics: 7 sponsored US clinical trials, 2 recruiting.

MoonLake Immunotherapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 5 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arthritis, Psoriatic, with 3 trials.

Upper-quartile sponsor footprint

MoonLake Immunotherapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

NCT06768671
RECRUITING Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089
ACTIVE NOT RECRUITING Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411899
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411379
COMPLETED Phase 2

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

NCT05640245
COMPLETED Phase 2

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 5

Therapeutic Areas

Arthritis, Psoriatic 3
Hidradenitis Suppurativa 3

Where MoonLake Immunotherapeutics enrollment is open (later-stage tilt)

2 recruiting of 7 indexed (29% open); 2 completed (29%).

Phase mix: 5 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Arthritis, Psoriatic (3 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

MoonLake Immunotherapeutics: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

MoonLake Immunotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share MoonLake Immunotherapeutics3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
MoonLake Immunotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

MoonLake Immunotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this MoonLake Immunotherapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of MoonLake Immunotherapeutics or any single study.

  • 2 of MoonLake Immunotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Arthritis, Psoriatic is the condition MoonLake Immunotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arthritis, Psoriatic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. MoonLake Immunotherapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.